Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus INDERAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus INDERAL.
CARVEDILOL vs INDERAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
None Documented
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Category C
Category C
Alpha/Beta-Blocker
Beta-Blocker